Literature DB >> 30309852

Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Solène M Evrard1,2,3, Sarah Péricart4, David Grand4, Nadia Amara4, Frédéric Escudié4, Julia Gilhodes5, Pierre Bories6, Alexandra Traverse-Glehen7, Romain Dubois8, Pierre Brousset4,2,3, Marie Parrens9, Camille Laurent4,2,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30309852      PMCID: PMC6442958          DOI: 10.3324/haematol.2018.198572

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Authors:  Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

2.  Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

Authors:  Daisuke Ennishi; Anja Mottok; Susana Ben-Neriah; Hennady P Shulha; Pedro Farinha; Fong Chun Chan; Barbara Meissner; Merrill Boyle; Christoffer Hother; Robert Kridel; Daniel Lai; Saeed Saberi; Ali Bashashati; Sohrab P Shah; Ryan D Morin; Marco A Marra; Kerry J Savage; Laurie H Sehn; Christian Steidl; Joseph M Connors; Randy D Gascoyne; David W Scott
Journal:  Blood       Date:  2017-03-28       Impact factor: 22.113

3.  MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.

Authors:  Shaoying Li; Parth Desai; Pei Lin; C Cameron Yin; Guilin Tang; Xuan J Wang; Sergej N Konoplev; Joseph D Khoury; Carlos E Bueso-Ramos; L Jeffrey Medeiros
Journal:  Histopathology       Date:  2015-12-08       Impact factor: 5.087

4.  Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Authors:  Daniel J Landsburg; Adam M Petrich; Jeremy S Abramson; Aliyah R Sohani; Oliver Press; Ryan Cassaday; Julio C Chavez; Kevin Song; Andrew D Zelenetz; Mitul Gandhi; Namrata Shah; Timothy S Fenske; Jesse Jaso; L Jeffrey Medeiros; David T Yang; Chadi Nabhan
Journal:  Cancer       Date:  2015-11-13       Impact factor: 6.860

5.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Authors:  Anupama Reddy; Jenny Zhang; Nicholas S Davis; Andrea B Moffitt; Cassandra L Love; Alexander Waldrop; Sirpa Leppa; Annika Pasanen; Leo Meriranta; Marja-Liisa Karjalainen-Lindsberg; Peter Nørgaard; Mette Pedersen; Anne O Gang; Estrid Høgdall; Tayla B Heavican; Waseem Lone; Javeed Iqbal; Qiu Qin; Guojie Li; So Young Kim; Jane Healy; Kristy L Richards; Yuri Fedoriw; Leon Bernal-Mizrachi; Jean L Koff; Ashley D Staton; Christopher R Flowers; Ora Paltiel; Neta Goldschmidt; Maria Calaminici; Andrew Clear; John Gribben; Evelyn Nguyen; Magdalena B Czader; Sarah L Ondrejka; Angela Collie; Eric D Hsi; Eric Tse; Rex K H Au-Yeung; Yok-Lam Kwong; Gopesh Srivastava; William W L Choi; Andrew M Evens; Monika Pilichowska; Manju Sengar; Nishitha Reddy; Shaoying Li; Amy Chadburn; Leo I Gordon; Elaine S Jaffe; Shawn Levy; Rachel Rempel; Tiffany Tzeng; Lanie E Happ; Tushar Dave; Deepthi Rajagopalan; Jyotishka Datta; David B Dunson; Sandeep S Dave
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

6.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

7.  Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Authors:  Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt
Journal:  N Engl J Med       Date:  2018-04-12       Impact factor: 91.245

8.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

9.  Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.

Authors:  Darius Juskevicius; David Jucker; Dirk Klingbiel; Christoph Mamot; Stephan Dirnhofer; Alexandar Tzankov
Journal:  J Hematol Oncol       Date:  2017-03-17       Impact factor: 17.388

10.  Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.

Authors:  Noel F C C de Miranda; Konstantinos Georgiou; Longyun Chen; Chenglin Wu; Zhibo Gao; Apostolos Zaravinos; Susana Lisboa; Gunilla Enblad; Manuel R Teixeira; Yixin Zeng; Roujun Peng; Qiang Pan-Hammarström
Journal:  Blood       Date:  2014-08-29       Impact factor: 22.113

View more
  9 in total

Review 1.  Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.

Authors:  Rebecca L King; Eric D Hsi; Wing C Chan; Miguel A Piris; James R Cook; David W Scott; Steven H Swerdlow
Journal:  Virchows Arch       Date:  2022-09-03       Impact factor: 4.535

2.  Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Jeffrey P Ward; Melissa M Berrien-Elliott; Felicia Gomez; Jingqin Luo; Michelle Becker-Hapak; Amanda F Cashen; Nina D Wagner-Johnston; Kami Maddocks; Matthew Mosior; Mark Foster; Kilannin Krysiak; Alina Schmidt; Zachary L Skidmore; Sweta Desai; Marcus P Watkins; Anne Fischer; Malachi Griffith; Obi L Griffith; Todd A Fehniger; Nancy L Bartlett
Journal:  Blood       Date:  2022-03-31       Impact factor: 25.476

3.  Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.

Authors:  Blanca Gonzalez-Farre; Joan Enric Ramis-Zaldivar; Julia Salmeron-Villalobos; Olga Balagué; Verónica Celis; Jaime Verdu-Amoros; Ferran Nadeu; Constantino Sábado; Antonio Ferrández; Marta Garrido; Federico García-Bragado; María Dolores de la Maya; José Manuel Vagace; Carlos Manuel Panizo; Itziar Astigarraga; Mara Andrés; Elaine S Jaffe; Elias Campo; Itziar Salaverria
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

4.  Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.

Authors:  Francesco Cucco; Sharon Barrans; Chulin Sha; Alexandra Clipson; Simon Crouch; Rachel Dobson; Zi Chen; Joe Sneath Thompson; Matthew A Care; Thomas Cummin; Josh Caddy; Hongxiang Liu; Anne Robinson; Anna Schuh; Jude Fitzgibbon; Daniel Painter; Alexandra Smith; Eve Roman; Reuben Tooze; Catherine Burton; Andrew J Davies; David R Westhead; Peter W M Johnson; Ming-Qing Du
Journal:  Leukemia       Date:  2019-12-16       Impact factor: 11.528

5.  Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.

Authors:  Fan Gao; Lei Tian; Hui Shi; Peihao Zheng; Jing Wang; Fei Dong; Kai Hu; Xiaoyan Ke
Journal:  Front Genet       Date:  2021-12-02       Impact factor: 4.599

6.  Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.

Authors:  Axel Künstner; Hanno M Witte; Jörg Riedl; Veronica Bernard; Stephanie Stölting; Hartmut Merz; Vito Olschewski; Wolfgang Peter; Julius Ketzer; Yannik Busch; Peter Trojok; Nikolas von Bubnoff; Hauke Busch; Alfred C Feller; Niklas Gebauer
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

7.  Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma.

Authors:  Shan-Shan Li; Xiao-Hui Zhai; Hai-Ling Liu; Ting-Zhi Liu; Tai-Yuan Cao; Dong-Mei Chen; Le-Xin Xiao; Xiao-Qin Gan; Ke Cheng; Wan-Jia Hong; Yan Huang; Yi-Fan Lian; Jian Xiao
Journal:  Exp Hematol Oncol       Date:  2022-10-15

8.  Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.

Authors:  Takahisa Yamashita; Claudia Vollbrecht; Burkhard Hirsch; Karsten Kleo; Ioannis Anagnostopoulos; Michael Hummel
Journal:  J Clin Exp Hematop       Date:  2020

9.  Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.

Authors:  Cédric Rossi; Marie Tosolini; Pauline Gravelle; Sarah Pericart; Salim Kanoun; Solene Evrard; Julia Gilhodes; Don-Marc Franchini; Nadia Amara; Charlotte Syrykh; Pierre Bories; Lucie Oberic; Loïc Ysebaert; Laurent Martin; Selim Ramla; Philippine Robert; Claire Tabouret-Viaud; René-Olivier Casasnovas; Jean-Jacques Fournié; Christine Bezombes; Camille Laurent
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.